Kevin specializes in rapidly commercializing early stage ideas into successful ventures. He has extensive experience in the innovation, development, and launch of novel technologies to develop new paradigms to measure complex biological information at unprecedented resolution. He previously co-founded QuantaLife and then 10x Genomics, helping bring to the world ddPCR, Linked-Read sequencing, and massively parallel single cell solutions. As a mechanical engineer, he is a true tool builder at heart, and has committed his life to building the best-in-class tools, chemistries and software for biologists.
Ryan T Gill
CSO & Co-Founder
Ryan is a co-founder of Inscripta and has established his career at the forefront of developing new genome engineering technologies. He has founded multiple successful technology start-ups across a broad application space. Ryan brings a strong background in corporate strategy, technology development, and intellectual property. Ryan was a key inventor of Inscripta’s foundational technology, which was developed at the University of Colorado, Boulder where he is the Slade Professor, Chemical and Biological Engineering and Executive Director of the BioDesign Center at the RAS Energy Institute. Ryan’s academic research focus bridges metabolic engineering and synthetic biology with a particular emphasis on the development of new engineering tools and technologies.
VP of Applications Development & Co-Founder
Tanya is a co-founder of Inscripta. She is an expert at managing complex technical programs and building high-performance teams. She has a proven track record of delivering success against cross-functional engineering projects, including multi-million dollar efforts focused on cost competitive biochemical production. Prior to Inscripta, Tanya oversaw the Metabolic Engineering and Genomics efforts at OPXBIO and was a key inventor on the core R&D innovation.
Erik has an extensive financial and accounting background spanning fifteen years and specializes in turning complex financial data into meaningful information for effecting decision making. He has built high-performing teams to provide robust, effective analysis and reporting at each step in his career. His expertise includes financing, controls and compliance, finance and treasury management, SEC and financial reporting and investor relations. Prior to Inscripta, Erik served as Controller at Metropolitan Merchant Capital and played a senior financial reporting role during ZAYO’s IPO in 2014. Erik began his career in public accounting at Ernst & Young. He earned B.S. degrees in Accounting and Finance at Indiana University-Bloomington and his CPA certification in 2002.
Don has a passion for building revolutionary tools for the Life Sciences community and has lead Engineering teams that have produced instruments currently changing the way science is done. As a previous Co-Founder of Quantalife and a former Director of Engineering for 10X Genomics he will continue innovate and build Best-in-Class tools for use with Inscripta technologies, moving applications for protein, pathway, and genome engineering to new levels.
Todd has been involved in leading teams of engineers, software developers and IT specialists to automate and integrate high production genomics labs for over 20 years. He specializes in using a systems engineering approach to functionally integrate lab robotics, data tracking systems (LIMS) and business systems into a seamless environment enabling lab technicians and R&D scientists to excel in achieving consistent and rapid results. Todd has been involved in the startup through production phases of operations at genomics focused companies including Myriad Genetics, Illumina and Ariosa Diagnostics (now part of Roche Sequencing Systems).
VP Product Development
Michael brings over 20 years of experience in technology and product development, having led teams that developed and commercialized foundational reagent and consumable products for Illumina’s microarray and next generation sequencing platforms. Prior to Illumina, Michael held positions at BioSite Diagnostics and the University of California. He brings a broad background in measurement science, surface modification, process engineering, device fabrication, and cross-functional team leadership. He holds a PhD in Chemical Physics from the University to California, San Diego. Michael is motivated to provide the scientific community with DNA editing tools to responsibly advance research, applied, and clinical markets.
Paul has developed products in the biotech field for over 20 years and has significant experience in bringing novel biochemistry to market for genomic applications. In his role at Inscripta, Paul leads enzyme engineering, cell biology and the development of gene editing tools. Paul holds a PhD in Biomedical Sciences from the University of Texas, Houston, and founded ParAllele Bioscience (acquired by Affymetrix in 2005.) Other past positions include Senior Director of Biochemistry at 10X Genomics, and Fellow at Pacific Biosciences.
Dianna is General Counsel of Inscripta, specializing in product protection strategies, transactional law and patent enforcement for life science companies. Dianna was previously Senior Vice President of Intellectual Property and Legal Affairs at Ariosa Diagnostics, Inc., acquired by Roche Molecular Systems in 2015. Dianna has been legal and IP counsel for various companies including Complete Genomics, Cambridge Antibody Technology (a wholly-owned subsidiary of AstraZeneca) and Elan Pharmaceuticals. In 2002, Dianna co-founded the Australian Stem Cell Centre (ASCC) in Melbourne, Australia, the first Australian Biotechnology Centre of Excellence. At the ASCC, Dianna was responsible for oversight of all operational, corporate, legal and intellectual property activities.